Cytokines and growth factors in the developing intestine and during necrotizing enterocolitis

Seminars in Perinatology

Volumn 41, Issue 1, 2017, Pages 52-60

  MohanKumar, Krishnan ^a   Namachivayam, Kopperuncholan ^a   Ho, Thao T B ^a   Torres, Benjamin A ^a   Ohls, Robin K ^b   Maheshwari, Akhil ^a,c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cytokines; Growth factors; Intestinal injury; NEC; Prevention

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; GROWTH FACTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR;

DISEASE MARKER; EARLY DIAGNOSIS; FETUS; HUMAN; INFLAMMATION; INTESTINE; INTESTINE DEVELOPMENT; INTESTINE INJURY; INTESTINE MUCOSA; MOLECULARLY TARGETED THERAPY; NECROTIZING ENTEROCOLITIS; NONHUMAN; ORGANOGENESIS; PATHOGENESIS; PATHOPHYSIOLOGY; PREDICTION; PROTEIN FUNCTION; REVIEW; DISEASE PREDISPOSITION; EXTREMELY LOW BIRTH WEIGHT; GENE EXPRESSION REGULATION; IMMUNOLOGY; INFANT NUTRITION; INNATE IMMUNITY; METABOLISM; NEWBORN; PREMATURITY;

CYTOKINES; DISEASE SUSCEPTIBILITY; ENTEROCOLITIS, NECROTIZING; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HEPARIN-BINDING EGF-LIKE GROWTH FACTOR; HUMANS; IMMUNITY, INNATE; INFANT NUTRITIONAL PHYSIOLOGICAL PHENOMENA; INFANT, EXTREMELY LOW BIRTH WEIGHT; INFANT, EXTREMELY PREMATURE; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; INFLAMMATION; INTESTINAL MUCOSA;

EID: 85006317199     PISSN: 01460005     EISSN: 1558075X     Source Type: Journal    
DOI: 10.1053/j.semperi.2016.09.018     Document Type: Review

References (108)

1. 1 Maheshwari, A., Lacson, A., Lu, W., et al. Interleukin-8/CXCL8 forms an autocrine loop in fetal intestinal mucosa. Pediatr Res 56:2 (2004), 240–249.
2. 2 Nanthakumar, N.N., Young, C., Ko, J.S., et al. Glucocorticoid responsiveness in developing human intestine: possible role in prevention of necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 288:1 (2005), G85–G92.
3. 3 Fusunyan, R.D., Nanthakumar, N.N., Baldeon, M.E., Walker, W.A., Evidence for an innate immune response in the immature human intestine: toll-like receptors on fetal enterocytes. Pediatr Res 49:4 (2001), 589–593.
4. 4 Nanthakumar, N.N., Fusunyan, R.D., Sanderson, I., Walker, W.A., Inflammation in the developing human intestine: A possible pathophysiologic contribution to necrotizing enterocolitis. Proc Natl Acad Sci U S A 97:11 (2000), 6043–6048.
5. 5 Daig, R., Rogler, G., Aschenbrenner, E., et al. Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6. Gut 46:3 (2000), 350–358.
6. 6 Martin, C.R., Walker, W.A., Intestinal immune defences and the inflammatory response in necrotising enterocolitis. Semin Fetal Neonatal Med 11:5 (2006), 369–377.
7. 7 Maheshwari, A., Kelly, D.R., Nicola, T., et al. TGF-β2 suppresses macrophage cytokine production and mucosal inflammatory responses in the developing intestine. Gastroenterology 140:1 (2011), 242–253.
8. 8 Nanthakumar, N., Meng, D., Goldstein, A.M., et al. The mechanism of excessive intestinal inflammation in necrotizing enterocolitis: an immature innate immune response. PloS One, 6(3), 2011, e17776.
9. 9 Claud, E.C., Lu, L., Anton, P.M., Savidge, T., Walker, W.A., Cherayil, B.J., Developmentally regulated IkappaB expression in intestinal epithelium and susceptibility to flagellin-induced inflammation. Proc Natl Acad Sci U S A 101:19 (2004), 7404–7408.
10. 10 Pritchard, J.A., Fetal swallowing and amniotic fluid volume. Obstet Gynecol 28:5 (1966), 606–610.
11. 11 Trahair, J.F., Harding, R., Ultrastructural anomalies in the fetal small intestine indicate that fetal swallowing is important for normal development: an experimental study. Virchows Arch A Pathol Anat Histopathol 420:4 (1992), 305–312.
12. 12 Trahair, J.F., Harding, R., Bocking, A.D., Silver, M., Robinson, P.M., The role of ingestion in the development of the small intestine in fetal sheep. Q J Exp Physiol 71:1 (1986), 99–104.
13. 13 Condino, A.A., Barleycorn, A.A., Lu, W., Maheshwari, A., Christensen, R.D., Calhoun, D.A., Abnormal intestinal histology in neonates with anomalies of the gastrointestinal tract. Biol Neonate 85 (2004), 145–150.
14. 14 Trahair, J.F., Harding, R., Restitution of swallowing in the fetal sheep restores intestinal growth after midgestation esophageal obstruction. J Pediatr Gastroenterol Nutr 20:2 (1995), 156–161.
15. 15 Hettinga, K.A., Reina, F.M., Boeren, S., et al. Difference in the breast milk proteome between allergic and non-allergic mothers. PloS One, 10(3), 2015, e0122234.
16. 16 Murphy, M.S., Growth factors and the gastrointestinal tract. Nutrition 14:10 (1998), 771–774.
17. 17 Takahata, Y., Takada, H., Nomura, A., et al. Interleukin-18 in human milk. Pediatr Res 50:2 (2001), 268–272.
18. 18 Britton, J.R., George-Nascimento, C., Udall, J.N., Koldovsky, O., Minimal hydrolysis of epidermal growth factor by gastric fluid of preterm infants. Gut 30:3 (1989), 327–332.
19. 19 Tremblay, E., Monfils, S., Menard, D., Epidermal growth factor influences cell proliferation, glycoproteins, and lipase activity in human fetal stomach. Gastroenterology 112:4 (1997), 1188–1196.
20. 20 Donovan, S.M., Hintz, R.L., Rosenfeld, R.G., Insulin-like growth factors I and II and their binding proteins in human milk: effect of heat treatment on IGF and IGF binding protein stability. J Pediatr Gastroenterol Nutr 13:3 (1991), 242–253.
21. 21 Bloomfield, F.H., Bauer, M.K., van Zijl, P.L., Gluckman, P.D., Harding, J.E., Amniotic IGF-I supplements improve gut growth but reduce circulating IGF-I in growth-restricted fetal sheep. Am J Physiol Endocrinol Metab 282:2 (2002), E259–E269.
22. 22 Burrin, D., Guan, X., Stoll, B., Petersen, Y.M., Sangild, P.T., Glucagon-like peptide 2: a key link between nutrition and intestinal adaptation in neonates?. J Nutr 133:11 (2003), 3712–3716.
23. 23 Burrin, D.G., Petersen, Y., Stoll, B., Sangild, P., Glucagon-like peptide 2: a nutrient-responsive gut growth factor. J Nutr 131:3 (2001), 709–712.
24. 24 Burrin, D.G., Stoll, B., Jiang, R., et al. GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis. Am J Physiol Gastrointest Liver Physiol 279:6 (2000), G1249–G1256.
25. 25 Vuorela, P., Andersson, S., Carpen, O., Ylikorkala, O., Halmesmaki, E., Unbound vascular endothelial growth factor and its receptors in breast, human milk, and newborn intestine. Am J Clin Nutr 72:5 (2000), 1196–1201.
26. 26 Chailler, P., Basque, J.R., Corriveau, L., Menard, D., Functional characterization of the keratinocyte growth factor system in human fetal gastrointestinal tract. Pediatr Res 48:4 (2000), 504–510.
27. 27 Maheshwari, A., Lu, W., Lacson, A., et al. Effects of interleukin-8 on the developing human intestine. Cytokine 20:6 (2002), 256–267.
28. 28 Lin, J., Nadroo, A.M., Chen, W., Holzman, I.R., Fan, Q.X., Babyatsky, M.W., Ontogeny and prenatal expression of trefoil factor 3/ITF in the human intestine. Early Hum Dev 71:2 (2003), 103–109.
29. 29 Lonergan, M., Aponso, D., Marvin, K.W., et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, and the soluble receptor osteoprotegerin in human gestational membranes and amniotic fluid during pregnancy and labor at term and preterm. J Clin Endocrinol Metab 88:8 (2003), 3835–3844.
30. 30 Waterhouse, C.C., Joseph, R.R., Stadnyk, A.W., Endogenous IL-1 and type II IL-1 receptor expression modulate anoikis in intestinal epithelial cells. Exp Cell Res 269:1 (2001), 109–116.
31. 31 Madsen, K.L., Inflammatory bowel disease: lessons from the IL-10 gene-deficient mouse. Clin Invest Med 24:5 (2001), 250–257.
32. 32 Davidson, A.J., Freeman, S.A., Crosier, K.E., Wood, C.R., Crosier, P.S., Expression of murine interleukin 11 and its receptor alpha-chain in adult and embryonic tissues. Stem Cells 15:2 (1997), 119–124.
33. 33 Welniak, L.A., Khaled, A.R., Anver, M.R., et al. Gastrointestinal cells of IL-7 receptor null mice exhibit increased sensitivity to irradiation. J Immunol 166:5 (2001), 2924–2928.
34. 34 Rollwagen, F.M., Yu, Z.Y., Li, Y.Y., Pacheco, N.D., IL-6 rescues enterocytes from hemorrhage induced apoptosis in vivo and in vitro by a bcl-2 mediated mechanism. Clin Immunol Immunopathol 89:3 (1998), 205–213.
35. 35 Hogaboam, C.M., Vallance, B.A., Kumar, A., et al. Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease. J Clin Invest 100:11 (1997), 2766–2776.
36. 36 Barmeyer, C., Horak, I., Zeitz, M., Fromm, M., Schulzke, J.D., The interleukin-2-deficient mouse model. Pathobiology 70:3 (2002), 139–142.
37. 37 Searle, R.F., Bromage, S.J., Palmer, J., Curry, J.E., Lang, A.K., Human amniotic fluid lacks interleukin-2 and interleukin-15 but can interact with the beta-chain of the interleukin-2 receptor. Immunology 99:3 (2000), 411–417.
38. 38 Maheshwari, A., Christensen, R.D., Calhoun, D.A., ELR+ CXC chemokines in human milk. Cytokine 24:3 (2003), 91–102.
39. 39 Henning, S.J., Rubin, D.C., Shulman, R.J., Ontogeny of the intestinal mucosa. Johnson, L., (eds.) Physiology of the Gastrointestinal Tract, 1994, Raven Press, New York, 571–610.
40. 40 Maheshwari, A., Role of cytokines in human intestinal villous development. Clin Perinatol 31:1 (2004), 143–155.
41. 41 Calhoun, D.A., Christensen, R.D., Hematopoietic growth factors in neonatal medicine: the use of enterally administered hematopoietic growth factors in the neonatal intensive care unit. Clin Perinatol 31:1 (2004), 169–182.
42. 42 Canpolat, F.E., Yurdakok, M., Korkmaz, A., Yigit, S., Tekinalp, G., Enteral granulocyte colony-stimulating factor for the treatment of mild (stage I) necrotizing enterocolitis: a placebo-controlled pilot study. J Pediatr Surg 41:6 (2006), 1134–1138.
43. 43 Hirai, C., Ichiba, H., Saito, M., Shintaku, H., Yamano, T., Kusuda, S., Trophic effect of multiple growth factors in amniotic fluid or human milk on cultured human fetal small intestinal cells. J Pediatr Gastroenterol Nutr 34:5 (2002), 524–528.
44. 44 Jain, S.K., Baggerman, E.W., Mohankumar, K., et al. Amniotic fluid-borne hepatocyte growth factor protects rat pups against experimental necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 306:5 (2014), G361–G369.
45. 45 Nakame, K., Kaji, T., Mukai, M., Shinyama, S., Matsufuji, H., The protective and anti-inflammatory effects of glucagon-like peptide-2 in an experimental rat model of necrotizing enterocolitis. Peptides 75 (2016), 1–7.
46. 46 Feng, J., El-Assal, O.N., Besner, G.E., Heparin-binding epidermal growth factor-like growth factor decreases the incidence of necrotizing enterocolitis in neonatal rats. J Pediatr Surg 41:1 (2006), 144–149 [discussion 9].
47. 47 Dvorak, B., Halpern, M.D., Holubec, H., et al. Epidermal growth factor reduces the development of necrotizing enterocolitis in a neonatal rat model. Am J Physiol Gastrointest Liver Physiol 282:1 (2002), G156–G164.
48. 48 Clark, J.A., Doelle, S.M., Halpern, M.D., et al. Intestinal barrier failure during experimental necrotizing enterocolitis: protective effect of EGF treatment. Am J Physiol Gastrointest Liver Physiol 291:5 (2006), G938–G949.
49. 49 Clark, J.A., Lane, R.H., Maclennan, N.K., et al. Epidermal growth factor reduces intestinal apoptosis in an experimental model of necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 288:4 (2005), G755–G762.
50. 50 Halpern, M.D., Holubec, H., Clark, J.A., et al. Epidermal growth factor reduces hepatic sequelae in experimental necrotizing enterocolitis. Biol Neonate 89:4 (2006), 227–235.
51. 51 Miettinen, P.J., Berger, J.E., Meneses, J., et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376:6538 (1995), 337–341.
52. 52 Warner, B.B., Ryan, A.L., Seeger, K., Leonard, A.C., Erwin, C.R., Warner, B.W., Ontogeny of salivary epidermal growth factor and necrotizing enterocolitis. J Pediatr 150:4 (2007), 358–363.
53. 53 Good, M., Siggers, R.H., Sodhi, C.P., et al. Amniotic fluid inhibits Toll-like receptor 4 signaling in the fetal and neonatal intestinal epithelium. Proc Natl Acad Sci U S A 109:28 (2012), 11330–11335.
54. 54 Besner, G., Higashiyama, S., Klagsbrun, M., Isolation and characterization of a macrophage-derived heparin-binding growth factor. Cell Regul 1:11 (1990), 811–819.
55. 55 Feng, J., Besner, G.E., Heparin-binding epidermal growth factor-like growth factor promotes enterocyte migration and proliferation in neonatal rats with necrotizing enterocolitis. J Pediatr Surg 42:1 (2007), 214–220.
56. 56 Feng, J., El-Assal, O.N., Besner, G.E., Heparin-binding epidermal growth factor-like growth factor reduces intestinal apoptosis in neonatal rats with necrotizing enterocolitis. J Pediatr Surg 41:4 (2006), 742–747 [discussion 7].
57. 57 Yu, X., Radulescu, A., Zorko, N., Besner, G.E., Heparin-binding EGF-like growth factor increases intestinal microvascular blood flow in necrotizing enterocolitis. Gastroenterology 137:1 (2009), 221–230.
58. 58 Wei, J., Besner, G.E., M1 to M2 macrophage polarization in heparin-binding epidermal growth factor-like growth factor therapy for necrotizing enterocolitis. J Surg Res 197:1 (2015), 126–138.
59. 59 Juul, S.E., Zhao, Y., Dame, J.B., Du, Y., Hutson, A.D., Christensen, R.D., Origin and fate of erythropoietin in human milk. Pediatr Res 48:5 (2000), 660–667.
60. 60 Ledbetter, D.J., Juul, S.E., Necrotizing enterocolitis and hematopoietic cytokines. Clin Perinatol 27:3 (2000), 697–716.
61. 61 Akisu, M., Kullahcioglu Girgin, F., Baka, M., Husseyinov, A., Kultursay, N., The role of recombinant human erythropoietin in lipid peroxidation and platelet-activating factor generation in a rat model of necrotizing enterocolitis. Eur J Pediatr Surg 11:3 (2001), 167–172.
62. 62 Kumral, A., Baskin, H., Duman, N., et al. Erythropoietin protects against necrotizing enterocolitis of newborn rats by the inhibiting nitric oxide formation. Biol Neonate 84:4 (2003), 325–329.
63. 63 Shiou, S.R., Yu, Y., Chen, S., et al. Erythropoietin protects intestinal epithelial barrier function and lowers the incidence of experimental neonatal necrotizing enterocolitis. J Biol Chem 286:14 (2011), 12123–12132.
64. 64 Yu, Y., Shiou, S.R., Guo, Y., et al. Erythropoietin protects epithelial cells from excessive autophagy and apoptosis in experimental neonatal necrotizing enterocolitis. PloS One, 8(7), 2013, e69620.
65. 65 McPherson, R.J., Juul, S.E., High-dose erythropoietin inhibits apoptosis and stimulates proliferation in neonatal rat intestine. Growth Horm IGF Res 17:5 (2007), 424–430.
66. 66 Calhoun, D.A., Maheshwari, A., Christensen, R.D., Recombinant granulocyte colony-stimulating factor administered enterally to neonates is not absorbed. Pediatrics 112:2 (2003), 421–423.
67. 67 Canpolat, F.E., Yurdakok, M., Ozsoy, S., Haziroglu, R., Korkmaz, A., Protective effects of recombinant human granulocyte colony stimulating factor in a rat model of necrotizing enterocolitis. Pediatr Surg Int 22:9 (2006), 719–723.
68. 68 Christensen, R.D., Havranek, T., Gerstmann, D.R., Calhoun, D.A., Enteral administration of a simulated amniotic fluid to very low birth weight neonates. J Perinatol 25:6 (2005), 380–385.
69. 69 Christensen, R.D., Lambert, D.K., Barney, C.K., Calhoun, D.A., Maheshwari, A., Lima-Rogel, V., Update on the SAFEstart Clinical Trials. Hematol Rep 2:10 (2006), 80–85.
70. 70 Roberge, J.N., Brubaker, P.L., Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients. Endocrinology 128:6 (1991), 3169–3174.
71. 71 Vegge, A., Thymann, T., Lund, P., et al. Glucagon-like peptide-2 induces rapid digestive adaptation following intestinal resection in preterm neonates. Am J Physiol Gastrointest Liver Physiol 305:4 (2013), G277–G285.
72. 72 Benight, N.M., Stoll, B., Olutoye, O.O., Holst, J.J., Burrin, D.G., GLP-2 delays but does not prevent the onset of necrotizing enterocolitis in preterm pigs. J Pediatr Gastroenterol Nutr 56:6 (2013), 623–630.
73. 73 Siggers, J., Ostergaard, M.V., Siggers, R.H., et al. Postnatal amniotic fluid intake reduces gut inflammatory responses and necrotizing enterocolitis in preterm neonates. Am J Physiol Gastrointest Liver Physiol 304:10 (2013), G864–G875.
74. 74 Kalliomaki, M., Ouwehand, A., Arvilommi, H., Kero, P., Isolauri, E., Transforming growth factor-beta in breast milk: a potential regulator of atopic disease at an early age. J Allergy Clin Immunol 104:6 (1999), 1251–1257.
75. 75 Letterio, J.J., Geiser, A.G., Kulkarni, A.B., Roche, N.S., Sporn, M.B., Roberts, A.B., Maternal rescue of transforming growth factor-beta 1 null mice. Science 264:5167 (1994), 1936–1938.
76. 76 Lebman, D.A., Edmiston, J.S., The role of TGF-beta in growth, differentiation, and maturation of B lymphocytes. Microbes Infect 1:15 (1999), 1297–1304.
77. 77 Hawkes, J.S., Bryan, D.L., James, M.J., Gibson, R.A., Cytokines (IL-1beta, IL-6, TNF-alpha, TGF-beta1, and TGF-beta2) and prostaglandin E2 in human milk during the first three months postpartum. Pediatr Res 46:2 (1999), 194–199.
78. 78 Rautava, S., Nanthakumar, N.N., Dubert-Ferrandon, A., Lu, L., Rautava, J., Walker, W.A., Breast milk-transforming growth factor-beta(2) specifically attenuates IL-1beta-induced inflammatory responses in the immature human intestine via an SMAD6- and ERK-dependent mechanism. Neonatology 99:3 (2011), 192–201.
79. 79 Namachivayam, K., Blanco, C.L., Frost, B.L., et al. Preterm human milk contains a large pool of latent TGF-beta, which can be activated by exogenous neuraminidase. Am J Physiol Gastrointest Liver Physiol 304:12 (2013), G1055–G1065.
80. 80 Namachivayam, K., Coffing, H.P., Sankaranarayanan, N.V., et al. Transforming growth factor-beta2 is sequestered in preterm human milk by chondroitin sulfate proteoglycans. Am J Physiol Gastrointest Liver Physiol 309:3 (2015), G171–G180.
81. 81 Frost, B.L., Jilling, T., Lapin, B., Maheshwari, A., Caplan, M.S., Maternal breast milk transforming growth factor-beta and feeding intolerance in preterm infants. Pediatr Res 76:4 (2014), 386–393.
82. 82 Shiou, S.R., Yu, Y., Guo, Y., et al. Oral administration of transforming growth factor-beta1 (TGF-beta1) protects the immature gut from injury via Smad protein-dependent suppression of epithelial nuclear factor kappaB (NF-kappaB) signaling and proinflammatory cytokine production. J Biol Chem 288:48 (2013), 34757–34766.
83. 83 Viscardi, R.M., Lyon, N.H., Sun, C.C., Hebel, J.R., Hasday, J.D., Inflammatory cytokine mRNAs in surgical specimens of necrotizing enterocolitis and normal newborn intestine. Pediatr Pathol Lab Med 17:4 (1997), 547–559.
84. 84 Caplan, M.S., Sun, X.M., Hseuh, W., Hageman, J.R., Role of platelet activating factor and tumor necrosis factor-alpha in neonatal necrotizing enterocolitis. J Pediatr 116:6 (1990), 960–964.
85. 85 Tan, X., Hsueh, W., Gonzalez-Crussi, F., Cellular localization of tumor necrosis factor (TNF)-alpha transcripts in normal bowel and in necrotizing enterocolitis. TNF gene expression by Paneth cells, intestinal eosinophils, and macrophages. Am J Pathol 142:6 (1993), 1858–1865.
86. 86 Chan, K.Y., Leung, K.T., Tam, Y.H., et al. Genome-wide expression profiles of necrotizing enterocolitis versus spontaneous intestinal perforation in human intestinal tissues: dysregulation of functional pathways. Ann Surg 260:6 (2014), 1128–1137.
87. 87 Edelson, M.B., Bagwell, C.E., Rozycki, H.J., Circulating pro- and counterinflammatory cytokine levels and severity in necrotizing enterocolitis. Pediatrics 103:4 Pt 1 (1999), 766–771.
88. 88 McILwain, R.B., Timpa, J.G., Kurundkar, A.R., et al. Plasma concentrations of inflammatory cytokines rise rapidly during ECMO-related SIRS due to the release of preformed stores in the intestine. Lab Invest 90:1 (2010), 128–139.
89. 89 Maheshwari, A., Schelonka, R.L., Dimmitt, R.A., et al. Cytokines associated with necrotizing enterocolitis in extremely-low-birth-weight infants. Pediatr Res 76:1 (2014), 100–108.
90. 90 Carlo, W.A., McDonald, S.A., Tyson, J.E., et al. Cytokines and neurodevelopmental outcomes in extremely low birth weight infants. J Pediatr 159:6 (2011), 919e3–925e3.
91. 91 Harris, M.C., Costarino, A.T. Jr., Sullivan, J.S., et al. Cytokine elevations in critically ill infants with sepsis and necrotizing enterocolitis. J Pediatr 124:1 (1994), 105–111.
92. 92 Ford, H.R., Sorrells, D.L., Knisely, A.S., Inflammatory cytokines, nitric oxide, and necrotizing enterocolitis. Semin Pediatr Surg 5:3 (1996), 155–159.
93. 93 Ng, P.C., Li, K., Wong, R.P., et al. Proinflammatory and anti-inflammatory cytokine responses in preterm infants with systemic infections. Arch Dis Child Fetal Neonatal Ed 88:3 (2003), F209–F213.
94. 94 Harris, M.C., D'Angio, C.T., Gallagher, P.R., Kaufman, D., Evans, J., Kilpatrick, L., Cytokine elaboration in critically ill infants with bacterial sepsis, necrotizing entercolitis, or sepsis syndrome: correlation with clinical parameters of inflammation and mortality. J Pediatr 147:4 (2005), 462–468.
95. 95 Benkoe, T., Baumann, S., Weninger, M., et al. Comprehensive evaluation of 11 cytokines in premature infants with surgical necrotizing enterocolitis. PloS One, 8(3), 2013, e58720.
96. 96 Lodha, A., Asztalos, E., Moore, A.M., Cytokine levels in neonatal necrotizing enterocolitis and long-term growth and neurodevelopment. Acta Paediatr 99:3 (2010), 338–343.
97. 97 Benkoe, T., Reck, C., Pones, M., et al. Interleukin-8 predicts 60-day mortality in premature infants with necrotizing enterocolitis. J Pediatr Surg 49:3 (2014), 385–389.
98. 98 Bhatia, A.M., Stoll, B.J., Cismowski, M.J., Hamrick, S.E., Cytokine levels in the preterm infant with neonatal intestinal injury. Am J Perinatol 31:6 (2014), 489–496.
99. 99 Sharma, R., Tepas, J.J. 3rd, Hudak, M.L., et al. Neonatal gut barrier and multiple organ failure: role of endotoxin and proinflammatory cytokines in sepsis and necrotizing enterocolitis. J Pediatr Surg 42:3 (2007), 454–461.
100. 100 MohanKumar, K., Namachivayam, K., Cheng, F., et al. Trinitrobenzene sulfonic acid-induced intestinal injury in neonatal mice activates transcriptional networks similar to those seen in human necrotizing enterocolitis. Pediatr Res(2), 2016, 10.1038/pr.2016.189 [Epub ahead of print].
101. 101 MohanKumar, K., Kaza, N., Jagadeeswaran, R., et al. Gut mucosal injury in neonates is marked by macrophage infiltration in contrast to pleomorphic infiltrates in adult: evidence from an animal model. Am J Physiol Gastrointest Liver Physiol 303:1 (2012), G93–G102.
102. 102 Wang, Y., Hoenig, J.D., Malin, K.J., et al. 16S rRNA gene-based analysis of fecal microbiota from preterm infants with and without necrotizing enterocolitis. ISME J 3:8 (2009), 944–954.
103. 103 Warner, B.B., Deych, E., Zhou, Y., et al. Gut bacteria dysbiosis and necrotising enterocolitis in very low birthweight infants: a prospective case-control study. Lancet 387:10031 (2016), 1928–1936.
104. 104 Maheshwari, A., Immunologic and hematological abnormalities in necrotizing enterocolitis. Clin Perinatol 42:3 (2015), 567–585.
105. 105 Dahle, C., Kvarnstrom, M., Ekerfelt, C., Samuelsson, M., Ernerudh, J., Elevated number of cells secreting transforming growth factor beta in Guillain-Barre syndrome. APMIS 111:12 (2003), 1095–1104.
106. 106 Namachivayam, K., Blanco, C.L., MohanKumar, K., et al. Smad7 inhibits autocrine expression of TGF-beta2 in intestinal epithelial cells in baboon necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 304:2 (2013), G167–G180.
107. 107 Halpern, M.D., Clark, J.A., Saunders, T.A., et al. Reduction of experimental necrotizing enterocolitis with anti-TNF-alpha. Am J Physiol Gastrointest Liver Physiol 290:4 (2006), G757–G764.
108. 108 Seitz, G., Warmann, S.W., Guglielmetti, A., et al. Protective effect of tumor necrosis factor alpha antibody on experimental necrotizing enterocolitis in the rat. J Pediatr Surg 40:9 (2005), 1440–1445.